Optimal Endovascular Therapy Technique for Isolated Intracranial Atherothrombotic Stroke-Related Large-Vessel Occlusion in the Acute-to-Subacute Stage
Mikiya Beppu,Kazutaka Uchida,Nobuyuki Sakai,Hiroshi Yamagami,Kazunori Toyoda,Yuji Matsumaru,Yasushi Matsumoto,Kenichi Todo,Mikito Hayakawa,Seigo Shindo,Shinzo Ota,Masafumi Morimoto,Masataka Takeuchi,Hirotoshi Imamura,Hiroyuki Ikeda,Kanta Tanaka,Hideyuki Ishihara,Hiroto Kakita,Takanori Sano,Hayato Araki,Tatsufumi Nomura,Fumihiro Sakakibara,Manabu Shirakawa,Shinichi Yoshimura,RESCUE AT-LVO Investigators,Hiroyuki Ohnishi,Kyoichi Watanabe,Yoshiki Yagita,Yoshifumi Tsuboi,Yukiko Enomoto,So Tokunaga,Keisuke Imai,Naoki Tokuda,Hiroyuki Ikedam,Masaru Hirohata,Hitoshi Hasegawa,Yukako Yazawa,Masato Inoue,Keigo Shigeta,Kazutaka Sonoda,Takeshi Uwatoko,Hidenori Ohishi,Yuri Sugiura,Yasushi Ueno,Kazuya Nakamura,Wataro Tsuruta,Takumi Asai,Ichiro Nakagawa,Kenichi Morita,Yoshitaka Yamada,Koichi Haraguchi,Takashi Mizobe,Kakuta Kiyohide,Makoto Hayase,Toshio Higashi,Kei Harada,Ichiro Nakahara,Naoki Toma,Junichi Ayabe,Takuya Kanamaru,Makoto Nakajima,Shinichiro Yoshida
DOI: https://doi.org/10.3174/ajnr.A8399
2024-11-07
Abstract:Background and purpose: Reocclusion after treatment is a concern in endovascular therapy for isolated intracranial atherothrombotic stroke-related large-vessel occlusion (AT-LVO). However, the optimal endovascular therapy technique for AT-LVO has not yet been investigated. This study evaluated the optimal endovascular therapy technique for AT-LVO in a real-world setting. Materials and methods: We conducted a historical, multicenter registry study at 51 centers that enrolled patients with AT-LVO. We divided the patients into 3 groups based on the endovascular therapy technique: mechanical thrombectomy alone, percutaneous transluminal angioplasty (PTA), and stent deployment. Mechanical thrombectomy alone was classified into the mechanical thrombectomy-only group; PTA and mechanical thrombectomy-PTA, into the PTA group; and mechanical thrombectomy-stent deployment, mechanical thrombectomy-PTA-stent deployment, PTA-stent deployment, and stent deployment-only into the stent group. The primary outcome was incidence of reocclusion of the treated vessels within 90 days of endovascular therapy completion. Results: We enrolled 770 patients and analyzed 509 patients. The rates in the mechanical thrombectomy-only, PTA, and stent deployment groups were 40.7%, 44.4%, and 14.9%, respectively. Incidence rate of residual stenosis >70% of final angiography was significantly higher in the mechanical thrombectomy-only group than in the PTA and stent deployment groups (mechanical thrombectomy-only versus PTA versus stent deployment: 34.5% versus 26.3% versus 13.2%, P = .002). Reocclusion rate was significantly lower in the PTA group than in the mechanical thrombectomy-only group (adjusted hazard ratio, 0.48; 95% CI, 0.29-0.80). Of the patients, 83.5% experienced reocclusion within 10 days after endovascular therapy. Alarmingly, a substantial subset (approximately 62.0%) of patients experienced reocclusion within 2 days of endovascular therapy. Incidence of mRS scores of 0-2 ninety days after endovascular therapy was not significantly different among the 3 groups. Incidences of symptomatic intracranial hemorrhage, any other intracranial hemorrhage, and death were not significantly different. Conclusions: Incidence rate of reocclusion was significantly lower in the PTA group than in the mechanical thrombectomy-only group. We found no meaningful difference in reocclusion rates between the stent deployment and mechanical thrombectomy-only groups. In Japan, glycoprotein IIb/IIIa inhibitors are not reimbursed. Therefore, PTA might be the preferred choice for AT-LVOs due to the higher reocclusion risk with mechanical thrombectomy-only. Reocclusion was likely to occur within 10 days, particularly within 2 days post-endovascular therapy.